StocksFundsScreenerSectorsWatchlists
BVS

BVS - Bioventus Inc. Stock Price, Fair Value and News

5.24USD+0.08 (+1.55%)Delayed as of 28 Mar 2024, 09:56 am ET

Market Summary

BVS
USD5.24+0.08
Delayedas of 28 Mar 2024, 09:56 am
1.55%

BVS Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

BVS Stock Price

View Fullscreen

BVS RSI Chart

BVS Valuation

Market Cap

322.5M

Price/Earnings (Trailing)

-2.06

Price/Sales (Trailing)

0.63

EV/EBITDA

-5.88

Price/Free Cashflow

40.4

BVS Price/Sales (Trailing)

BVS Profitability

EBT Margin

-23.64%

Return on Equity

-70.65%

Return on Assets

-19.27%

Free Cashflow Yield

2.48%

BVS Fundamentals

BVS Revenue

Revenue (TTM)

512.3M

Rev. Growth (Yr)

7.62%

Rev. Growth (Qtr)

12.11%

BVS Earnings

Earnings (TTM)

-156.2M

Earnings Growth (Yr)

80.91%

Earnings Growth (Qtr)

16.53%

Breaking Down BVS Revenue

52 Week Range

0.805.32
(Low)(High)

Last 7 days

-0.2%

Last 30 days

20.1%

Last 90 days

4.0%

Trailing 12 Months

236.4%

How does BVS drawdown profile look like?

BVS Financial Health

Current Ratio

1.53

Debt/Equity

1.7

Debt/Cashflow

0.04

BVS Investor Care

Shares Dilution (1Y)

1.33%

Diluted EPS (TTM)

-2.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023513.9M510.6M502.8M512.3M
2022466.4M496.9M516.7M512.1M
2021324.3M376.1M399.1M430.9M
2020335.4M330.7M325.9M321.2M
2019000340.1M
2018000319.2M

Tracking the Latest Insider Buys and Sells of Bioventus Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 22, 2024
singleton mark leonard
sold
-29,852
5.3876
-5,541
svp & cfo
Mar 21, 2024
singleton mark leonard
acquired
-
-
18,625
svp & cfo
Mar 15, 2024
church katrina j
sold
-6,644
5.46
-1,217
svp & chief compliance officer
Mar 15, 2024
d'adamio anthony
sold
-17,062
5.46
-3,125
svp & general counsel
Mar 14, 2024
church katrina j
acquired
-
-
3,456
svp & chief compliance officer
Mar 14, 2024
d'adamio anthony
acquired
-
-
8,886
svp & general counsel
Aug 18, 2023
bihl anthony p iii
bought
110,071
4.1388
26,595
interim ceo
Aug 18, 2023
bihl anthony p iii
bought
55,004
4.1388
13,290
interim ceo
Aug 16, 2023
nohra guy p
acquired
-
-
41,369
-
Aug 16, 2023
nohra guy p
sold
-
-
-2,604,260
-

1–10 of 50

Which funds bought or sold BVS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
1.45
2,457,930
6,421,500
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
new
-
362,428
362,428
-%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-66,000
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
sold off
-100
-207,000
-
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
sold off
-100
-4,000
-
-%
Feb 15, 2024
BARCLAYS PLC
added
65.21
195,000
314,000
-%
Feb 15, 2024
State of Wyoming
reduced
-43.21
-6,240
60,842
0.01%
Feb 15, 2024
JANE STREET GROUP, LLC
added
398
717,154
820,276
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
98.64
43,141,400
63,002,500
1.88%
Feb 14, 2024
ExodusPoint Capital Management, LP
new
-
184,000
184,000
-%

1–10 of 46

Are Funds Buying or Selling BVS?

Are funds buying BVS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BVS
No. of Funds

Unveiling Bioventus Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
nantahala capital management, llc
9.5%
5,977,471
SC 13G/A
Feb 06, 2024
amp-cf holdings, llc
5.17%
3,255,332
SC 13G/A
Jan 22, 2024
ew healthcare partners acquisition fund, l.p.
19.2%
12,096,702
SC 13G/A
Jun 16, 2023
juniper investment company, llc
7.4%
4,624,431
SC 13D/A
May 24, 2023
juniper investment company, llc
7.4%
4,624,431
SC 13D/A
Feb 14, 2023
nantahala capital management, llc
5.1%
3,168,574
SC 13G
Feb 07, 2023
amp-cf holdings, llc
5.25%
3,255,332
SC 13G/A
Nov 15, 2022
juniper investment company, llc
5.4%
3,347,758
SC 13D/A
Jul 21, 2022
juniper investment company, llc
3.3%
2,051,172
SC 13D
Feb 11, 2022
amp-cf holdings, llc
5.47%
3,255,332
SC 13G

Recent SEC filings of Bioventus Inc.

View All Filings
Date Filed Form Type Document
Mar 27, 2024
144
Notice of Insider Sale Intent
Mar 25, 2024
144
Notice of Insider Sale Intent
Mar 25, 2024
4
Insider Trading
Mar 22, 2024
4
Insider Trading
Mar 22, 2024
4
Insider Trading
Mar 22, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
S-8
Employee Benefits Plan
Mar 18, 2024
4
Insider Trading

Peers (Alternatives to Bioventus Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.9B
40.1B
-3.02% 19.11%
34.4
4.91
-8.12% -17.45%
71.2B
19.5B
2.28% 4.53%
56.69
3.65
4.02% -22.04%
24.6B
3.9B
3.45% 0.50%
55.33
6.38
3.42% 23.09%
21.7B
14.8B
1.75% 11.60%
8.16
1.46
2.12% 209.17%
MID-CAP
10.2B
2.7B
2.92% -30.26%
-16.04
3.83
-4.68% 82.43%
9.7B
12.3B
-3.34% -3.19%
23.21
0.78
-2.44% -22.68%
9.5B
3.5B
2.97% 25.27%
33.57
2.74
4.97% 18.89%
6.9B
4.0B
-2.47% -11.08%
-51.36
1.74
1.10% 85.84%
3.5B
366.4M
0.74% 28.92%
-577.22
9.59
33.86% 89.80%
2.5B
6.6B
-3.84% 3.03%
12.86
0.38
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
47.53% -25.51%
-2.23
0.47
7.73% -1066.14%
379.3M
166.7M
5.16% -2.53%
-4.59
2.28
6.67% -456.34%
227.2M
329.5M
-13.41% -54.45%
-16.09
0.69
0.49% 64.22%
43.3M
52.3M
-46.12% -38.06%
-2.31
0.83
17.61% 19.28%
4.5M
3.7M
2.40% 338.46%
-0.37
1.19
5.77% 8.23%

Bioventus Inc. News

Latest updates
Defense World • 26 Mar 2024 • 09:05 am
MarketBeat • 26 Mar 2024 • 01:35 am
Investing.com • 25 Mar 2024 • 10:39 pm
Investing.com • 20 Mar 2024 • 11:45 pm
CNN • 20 Mar 2024 • 11:39 am
Seeking Alpha • 12 Mar 2024 • 03:00 pm

Bioventus Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Revenue12.1%13512113711912612914011713010911082.0099.0086.0058.0079.00--
Gross Profit9.4%86.0079.0089.0074.0074.0085.0097.0076.0088.0079.0076.0060.0073.0062.0040.0057.00--
  S&GA Expenses12.2%78.0070.0075.0081.0078.0079.0090.0086.0081.0070.0069.0035.0062.0050.0041.0040.00--
  R&D Expenses8.2%3.003.003.004.008.005.006.007.007.006.005.001.003.004.003.002.00--
EBITDA Margin45.0%-0.22*-0.40*-0.63*-0.63*-0.47*-0.29*-0.05*-0.06*0.04*0.06*0.09*0.12*0.07*0.05*0.05*0.05*0.05*0.05*
Income Taxes-225.0%-0.751.000.00-0.15-17.10-29.521.00-5.13-2.72-0.882.00-0.071.000.00-0.110.00--
Earnings Before Taxes-2.6%-8.41-8.19-4.35-100-107-130-6.49-19.54-4.62-3.15-9.0724.003.008.00-6.0911.00--
EBT Margin46.0%-0.24*-0.44*-0.67*-0.67*-0.52*-0.31*-0.07*-0.08*0.02*0.04*0.07*0.09*0.05*0.03*0.03*0.03*0.03*0.02*
Net Income16.5%-6.10-7.30-3.68-139-31.93-108-7.25-11.28-0.36-1.07-4.13-1.043.008.00-5.7711.00--
Net Income Margin15.8%-0.30*-0.36*-0.55*-0.56*-0.31*-0.25*-0.04*-0.04*-0.02*0.04*0.04*0.05*0.05*0.02*0.02*0.02*0.02*-0.04*
Free Cashflow196.7%10.00-10.359.00-1.072.00-2.351.00-23.9810.009.0016.00-19.4111.0020.007.0017.00--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets0.0%8118118378871,3731,3981,2091,1971,226655647643494472
  Current Assets7.4%268249261309273271277245263246290271212183
    Cash Equivalents37.8%37.0027.0029.0047.0030.0034.0041.0083.0099.0013113812987.0065.00
  Inventory-6.4%91.0098.0096.0088.0085.0077.0069.0065.0062.0037.0034.0040.0029.0027.00
  Net PPE--------25.0023.0010.009.008.007.004.00
  Goodwill0%7.007.007.007.007.0015.0060.0014814853.0052.003.0050.0050.00
Liabilities0.9%5905856046479601,019689675618424427423350327
  Current Liabilities9.1%17516117919630428819917218116115814912389.00
  Long Term Debt-100.0%-375375404385393351348340162166170173188
    LT Debt, Current42.2%28.0020.0011.0041.0033.0031.0023.0020.0018.0015.0015.0015.0015.0010.00
    LT Debt, Non Current-2.1%367375375404385393351348340162166170173188
Shareholder's Equity24.6%221178233240325451592594608230219220144143
  Retained Earnings-1.9%-321-315-308-304-165-133-25.13-17.88-6.60-6.24-5.17-1.04-144-141
  Additional Paid-In Capital0.4%494492491492491478474468473158146143--
Shares Outstanding-100.0%-62.0062.0062.0061.0062.0061.0060.0045.0042.0042.0042.00--
Minority Interest-2.9%48.0049.0050.0052.0087.0036.0072.0072.0014178.0078.0078.002.003.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Cashflow From Operations224.8%10,374-8,31510,7952,4905,244-7012,939-21,01913,11710,58717,329-18,04225,44720,8417,82017,691--
  Share Based Compensation-3.2%1,7751,833-2,7321,8463,4324,6484,6164,8896,1095,9385,8531,944------
Cashflow From Investing71.0%-591-2,03633,500-15,066-3,403-56,334-52,025-4,674-221,278-13,186-2,648-46,648-1,711-17,759-579-451--
Cashflow From Financing-100.2%-14.008,229-62,24827,380-5,43850,6547,6559,205176,308-4,346-6,117107,526-9,878-57,116-11,35748,782--

BVS Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net sales$ 512,345$ 512,117$ 430,898
Cost of sales (including depreciation and amortization of $48,503, $45,622 and $26,471 respectively)184,152181,037128,192
Gross profit328,193331,080302,706
Selling, general and administrative expense303,879332,134254,253
Research and development expense13,44623,85419,039
Restructuring costs8406,7792,487
Change in fair value of contingent consideration7191,102829
Depreciation and amortization8,8429,7488,363
Impairment of assets78,61500
Impairment of goodwill0124,6970
Loss on disposals3,57700
Impairment of variable interest entity assets005,674
Operating (loss) income(81,725)(167,234)12,061
Interest expense, net40,67612,0211,112
Other (income) expense(1,290)9,7701,461
Other expense39,38621,7912,573
(Loss) income before income taxes(121,111)(189,025)9,488
Income tax expense (benefit), net85(44,374)(1,966)
Net (loss) income from continuing operations(121,196)(144,651)11,454
Loss from discontinued operations, net of tax(74,429)(68,740)(1,868)
Net (loss) income(195,625)(213,391)9,586
Loss attributable to noncontrolling interest - continuing operations24,45840,7329,789
Loss attributable to noncontrolling interest - discontinued operations14,93713,9550
Net (loss) income attributable to Bioventus Inc.(156,230)(158,704)19,375
Change in prior service cost and unrecognized (loss) gain for defined benefit plan adjustment(8)13360
Change in foreign currency translation adjustments1,140(501)(1,318)
Comprehensive (loss) income(194,493)(213,759)8,328
Comprehensive loss attributable to noncontrolling interest - continuing operations24,23040,8119,789
Comprehensive loss attributable to noncontrolling interest - discontinued operations14,93713,9550
Comprehensive (loss) income attributable to Bioventus Inc.$ (155,326)$ (158,993)$ 18,117
Loss per share of Class A common stock   
Continuing operations, basic (in dollars per share)[1]$ (1.54)$ (1.70)$ (0.11)
Continuing operations, diluted (in dollars per share)[1](1.54)(1.70)(0.11)
Discontinued operations, basic (in dollars per share)[1](0.95)(0.89)(0.04)
Discontinued operations, diluted (in dollars per share)[1](0.95)(0.89)(0.04)
Basic (in dollars per share)[1](2.49)(2.59)(0.15)
Diluted (in dollars per share)[1]$ (2.49)$ (2.59)$ (0.15)
Weighted-average shares of Class A common stock outstanding   
Basic (in shares)[1]62,647,55461,389,10745,472,483
Diluted (in shares)[1]62,647,55461,389,10745,472,483
[1]
(1) Per share information for the year ended December 31, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through December 31, 2021, the period following Bioventus Inc.'s initial public offering and related transactions described in Note 8. Stockholders’ equity and Note 9. Earnings per share within the Notes to the Consolidated Financial Statements.

BVS Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 36,964$ 30,186
Accounts receivable, net122,789136,295
Inventory91,33384,766
Prepaid and other current assets16,91318,551
Current assets attributable to discontinued operations02,777
Total current assets267,999272,575
Property and equipment, net36,60527,456
Goodwill7,4627,462
Intangible assets, net482,350639,851
Operating lease assets13,35316,690
Investment and other assets3,1412,621
Long-term assets attributable to discontinued operations0405,994
Total assets810,9101,372,649
Current liabilities:  
Accounts payable23,03836,697
Accrued liabilities119,795111,570
Current portion of long-term debt27,84833,056
Other current liabilities4,8163,607
Current liabilities attributable to discontinued operations0119,087
Total current liabilities175,497304,017
Long-term debt, less current portion366,998385,010
Deferred income taxes1,2132,248
Contingent consideration18,15017,431
Other long-term liabilities27,93422,810
Long-term liabilities attributable to discontinued operations0228,911
Total liabilities589,792960,427
Commitments and contingencies (Note 12)
Stockholders’ Equity:  
Additional paid-in capital494,254490,576
Accumulated deficit(321,536)(165,306)
Accumulated other comprehensive income (loss)794(110)
Total stockholders’ equity attributable to Bioventus Inc.173,591325,238
Noncontrolling interest47,52786,984
Total stockholders’ equity221,118412,222
Total liabilities and stockholders’ equity810,9101,372,649
Common Class A  
Stockholders’ Equity:  
Common stock, value6362
Common Class B  
Stockholders’ Equity:  
Common stock, value$ 16$ 16
BVS
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
 CEO
 WEBSITEwww.bioventus.com
 EMPLOYEES950

Bioventus Inc. Frequently Asked Questions


What is the ticker symbol for Bioventus Inc.? What does BVS stand for in stocks?

BVS is the stock ticker symbol of Bioventus Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bioventus Inc. (BVS)?

As of Wed Mar 27 2024, market cap of Bioventus Inc. is 322.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BVS stock?

You can check BVS's fair value in chart for subscribers.

What is the fair value of BVS stock?

You can check BVS's fair value in chart for subscribers. The fair value of Bioventus Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bioventus Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BVS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bioventus Inc. a good stock to buy?

The fair value guage provides a quick view whether BVS is over valued or under valued. Whether Bioventus Inc. is cheap or expensive depends on the assumptions which impact Bioventus Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BVS.

What is Bioventus Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, BVS's PE ratio (Price to Earnings) is -2.06 and Price to Sales (PS) ratio is 0.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BVS PE ratio will change depending on the future growth rate expectations of investors.